Heads of R&D at all major pharma companies have come together to express their concerns about severe disruption to the European Medicines Agency (EMA) as it faces a Brexit-induced reloc
The UK government will shortly trigger Brexit under Article 50, opening up negotiations which are expected to see the country leave the European Union by March 2019.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.